Statins Provide Greater Cardiovascular Protection in HIV-Infected Individuals

Strategic Insights -

A recent study published in the AIDS journal suggests that statins, commonly used to lower cholesterol levels, may offer additional cardiovascular benefits for individuals with HIV infection beyond what is expected from their cholesterol-lowering effects. The research found that statin use was associated with a suppression of Th1-type immune responses, which are thought to contribute to the progression of cardiovascular disease. This finding has significant implications for the management of cardiovascular disease in HIV-infected individuals.

Key Takeaways:

  • The study included 1041 HIV-infected individuals, of whom 130 (12.5%) were receiving statin therapy.
  • Statin-treated individuals were older (60 vs. 49 years) and more frequently male (92% vs. 84%) compared to those not receiving statins.
  • In unadjusted analyses, there were no significant differences in the odds of elevated markers of Th1 immune responses between the two groups.
  • After multivariable adjustment, statin exposure was associated with lower odds of high kynurenine-to-tryptophan ratio (OR: 0.60; 95% CI 0.37-0.98), IFN-g (OR 0.58; 95% CI 0.36-0.92), and neopterin (OR 0.58; 95% CI 0.36-0.92).
  • The research concluded that these findings support a lipid-independent, immunomodulatory mechanism by which statins may confer cardiovascular protection in HIV infection.

Statistics:

  • 1041 HIV-infected individuals were included in the study.
  • 130 (12.5%) of the participants were receiving statin therapy.
  • Statin-treated individuals were 11 years older on average compared to those not receiving statins.
  • The odds of high kynurenine-to-tryptophan ratio, IFN-g, and neopterin levels were significantly lower in statin-treated individuals (OR: 0.60, 0.58, and 0.58, respectively).
  • The study found no significant associations between statin use and IL-6, IL-1b, or soluble CD14 levels.

Sources:

  • NewsRx. Study Results from University of Copenhagen Update Understanding of HIV/AIDS (Inhibition of Th1-type immune responses in persons with HIV with current statin exposure). AIDS Weekly. October 20, 2025; p 242.
  • Inhibition of Th1-type immune responses in persons with HIV with current statin exposure. AIDS, 2025.
  • Lippincott Williams & Wilkins, Two Commerce Sq, 2001 Market St, Philadelphia, PA 19103, USA. (Lippincott Williams and Wilkins - www.lww.com; AIDS - journals.lww.com/aidsonline/pages/default.aspx)